Krystal Biotech Q4 2025 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy KRYS?
Source: seekingalpha
- Significant Sales Growth: Krystal Biotech reported net revenue of $107.1 million for Q4 2025, marking nearly a 10% increase from the previous quarter and an 18% rise year-over-year, indicating strong market demand and enhanced sales capacity.
- International Expansion Plans: The company signed distributor agreements covering over 20 countries and aims to expand to more than 40 countries in 2026, reflecting its proactive global market strategy and commitment to international growth.
- High Gross Margin Maintenance: The gross margin for Q4 was 94%, with expectations to remain in the 90% to 95% range moving forward, demonstrating the company's strong performance in cost control and profitability despite rising costs.
- Investment in R&D and Marketing: The guidance for 2026 non-GAAP operating expenses is set at approximately $175 million to $195 million, reflecting ongoing investments in global launches and pipeline development, aimed at supporting future growth and innovation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 274.210
Low
198.00
Averages
229.25
High
278.00
Current: 274.210
Low
198.00
Averages
229.25
High
278.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Vertex Pharmaceuticals Faces Challenges in Cystic Fibrosis Market Dominance
- Market Dominance: Over the past decade, Vertex Pharmaceuticals has delivered market-beating returns primarily due to its monopoly in the cystic fibrosis drug market, which provides stable revenue but also exposes the company to threats from new entrants.
- Competitive Drug Development: Krystal Biotech's KB407 gene therapy has shown promising results in phase 1 studies, targeting all cystic fibrosis patients, while Vertex's drugs only address specific mutations, potentially leading to a loss of market share for Vertex.
- Diversification Strategy: To counter potential competition, Vertex has actively diversified its product lineup over the past three years, launching new drugs like Casgevy for sickle cell disease and Journavx for acute pain, with expectations for more approvals in the coming years.
- Strong Financial Performance: Despite facing competitive risks, Vertex is expected to continue delivering strong financial results, with its core products protected by patents until the late 2030s, making its stock still attractive for investors.
See More
Vertex Pharmaceuticals Faces Competitive Threats
- Market Competition Risk: Vertex Pharmaceuticals faces significant threats as companies like Krystal Biotech develop new cystic fibrosis drugs, particularly KB407, which has the potential to treat all CF patients and could lead to Vertex losing market share for 95% of U.S. patients.
- Core Business Security: Despite the competitive landscape, Vertex's core franchise appears secure for the foreseeable future, primarily due to its monopoly in the cystic fibrosis drug market, with key products protected by patents until the late 2030s.
- Product Diversification Strategy: Vertex is actively pursuing diversification of its product lineup, having launched new drugs like Casgevy and Journavx over the past three years, and is expected to gain additional approvals in the coming years, enhancing its competitive edge.
- R&D Progress: Vertex recently reported strong phase 3 results for povetacicept, an investigational drug for IgA nephropathy, and plans to announce more phase 3 results by year-end, potentially leading to regulatory approvals for treatments targeting APOL1-mediated kidney disease, further solidifying its market position.
See More
Krystal Biotech Shares Surge Over 230% Since 2021
- Innovative Drug Approval: In 2023, Krystal Biotech received FDA approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa (DEB), marking it as the first approved treatment for this condition, showcasing the company's strength in drug innovation.
- Significant Sales Growth: In 2025, Krystal Biotech's revenue increased by 34% year-over-year to $389.1 million, and the company achieved profitability with earnings per share of $6.84 in 2024, indicating strong performance and pricing power in the DEB market.
- Huge Market Potential: The company targets approximately 1,200 DEB patients in the U.S. and around 1,300 in Japan and some European nations, with unmet market needs suggesting significant opportunities for further market share expansion through new product launches.
- Long-Term Uncertainty: Despite strong performance in the DEB sector, Krystal Biotech faces potential competition and clinical or regulatory risks, making its ability to sustain growth uncertain, thus investors should carefully assess its long-term investment value.
See More
Krystal Biotech Shares Surge Over 230% Since 2021
- Strong Market Performance: Krystal Biotech's stock has surged over 230% since 2021, and despite having only one marketed product, its promising drug pipeline indicates significant growth potential, positioning it as a key player in the biotech sector.
- Innovative Therapy Approval: In 2023, Krystal Biotech received FDA approval for Vyjuvek, the first gene therapy for Dystrophic Epidermolysis Bullosa (DEB), addressing a critical unmet need in the market and further solidifying the company's market position.
- Solid Financial Performance: In 2025, the company reported a 34% year-over-year revenue increase to $389.1 million, with earnings per share at $6.84, showcasing a rare achievement of profitability in the biotech space, which boosts investor confidence.
- Future Growth Potential: Krystal Biotech's pipeline includes candidates for cystic fibrosis and alpha-1 antitrypsin deficiency lung disease, and if successful in launching new products, it could significantly enhance sales and profits, driving sustained growth over the next two decades.
See More
Palvella Appoints New Senior VP of Market Access
- Executive Appointment: Palvella Therapeutics has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services, leveraging her successful experience at Krystal Biotech to bolster support for the company's QTORIN™ programs.
- Market Access Strategy: During her tenure at Krystal Biotech, McDonough played a pivotal role in driving VYJUVEK® from FDA approval to $389 million in annual sales by 2025, showcasing her deep expertise in the rare disease market.
- Product Launch Preparation: Palvella is gearing up for a potential U.S. launch of QTORIN™ rapamycin, and McDonough's addition will enhance the company's capabilities in payer engagement and patient support, ensuring swift market entry for the product.
- Patient-First Philosophy: McDonough expressed enthusiasm for Palvella's unwavering patient-first approach, committing to ensure that QTORIN™ rapamycin reaches patients quickly and effectively, thereby enhancing the company's market position in the rare disease sector.
See More
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Vertex Pharmaceuticals Faces Challenges in Cystic Fibrosis Market Dominance
- Market Dominance: Over the past decade, Vertex Pharmaceuticals has delivered market-beating returns primarily due to its monopoly in the cystic fibrosis drug market, which provides stable revenue but also exposes the company to threats from new entrants.
- Competitive Drug Development: Krystal Biotech's KB407 gene therapy has shown promising results in phase 1 studies, targeting all cystic fibrosis patients, while Vertex's drugs only address specific mutations, potentially leading to a loss of market share for Vertex.
- Diversification Strategy: To counter potential competition, Vertex has actively diversified its product lineup over the past three years, launching new drugs like Casgevy for sickle cell disease and Journavx for acute pain, with expectations for more approvals in the coming years.
- Strong Financial Performance: Despite facing competitive risks, Vertex is expected to continue delivering strong financial results, with its core products protected by patents until the late 2030s, making its stock still attractive for investors.
See More
Vertex Pharmaceuticals Faces Competitive Threats
- Market Competition Risk: Vertex Pharmaceuticals faces significant threats as companies like Krystal Biotech develop new cystic fibrosis drugs, particularly KB407, which has the potential to treat all CF patients and could lead to Vertex losing market share for 95% of U.S. patients.
- Core Business Security: Despite the competitive landscape, Vertex's core franchise appears secure for the foreseeable future, primarily due to its monopoly in the cystic fibrosis drug market, with key products protected by patents until the late 2030s.
- Product Diversification Strategy: Vertex is actively pursuing diversification of its product lineup, having launched new drugs like Casgevy and Journavx over the past three years, and is expected to gain additional approvals in the coming years, enhancing its competitive edge.
- R&D Progress: Vertex recently reported strong phase 3 results for povetacicept, an investigational drug for IgA nephropathy, and plans to announce more phase 3 results by year-end, potentially leading to regulatory approvals for treatments targeting APOL1-mediated kidney disease, further solidifying its market position.
See More
Krystal Biotech Shares Surge Over 230% Since 2021
- Innovative Drug Approval: In 2023, Krystal Biotech received FDA approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa (DEB), marking it as the first approved treatment for this condition, showcasing the company's strength in drug innovation.
- Significant Sales Growth: In 2025, Krystal Biotech's revenue increased by 34% year-over-year to $389.1 million, and the company achieved profitability with earnings per share of $6.84 in 2024, indicating strong performance and pricing power in the DEB market.
- Huge Market Potential: The company targets approximately 1,200 DEB patients in the U.S. and around 1,300 in Japan and some European nations, with unmet market needs suggesting significant opportunities for further market share expansion through new product launches.
- Long-Term Uncertainty: Despite strong performance in the DEB sector, Krystal Biotech faces potential competition and clinical or regulatory risks, making its ability to sustain growth uncertain, thus investors should carefully assess its long-term investment value.
See More
Krystal Biotech Shares Surge Over 230% Since 2021
- Strong Market Performance: Krystal Biotech's stock has surged over 230% since 2021, and despite having only one marketed product, its promising drug pipeline indicates significant growth potential, positioning it as a key player in the biotech sector.
- Innovative Therapy Approval: In 2023, Krystal Biotech received FDA approval for Vyjuvek, the first gene therapy for Dystrophic Epidermolysis Bullosa (DEB), addressing a critical unmet need in the market and further solidifying the company's market position.
- Solid Financial Performance: In 2025, the company reported a 34% year-over-year revenue increase to $389.1 million, with earnings per share at $6.84, showcasing a rare achievement of profitability in the biotech space, which boosts investor confidence.
- Future Growth Potential: Krystal Biotech's pipeline includes candidates for cystic fibrosis and alpha-1 antitrypsin deficiency lung disease, and if successful in launching new products, it could significantly enhance sales and profits, driving sustained growth over the next two decades.
See More
Palvella Appoints New Senior VP of Market Access
- Executive Appointment: Palvella Therapeutics has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services, leveraging her successful experience at Krystal Biotech to bolster support for the company's QTORIN™ programs.
- Market Access Strategy: During her tenure at Krystal Biotech, McDonough played a pivotal role in driving VYJUVEK® from FDA approval to $389 million in annual sales by 2025, showcasing her deep expertise in the rare disease market.
- Product Launch Preparation: Palvella is gearing up for a potential U.S. launch of QTORIN™ rapamycin, and McDonough's addition will enhance the company's capabilities in payer engagement and patient support, ensuring swift market entry for the product.
- Patient-First Philosophy: McDonough expressed enthusiasm for Palvella's unwavering patient-first approach, committing to ensure that QTORIN™ rapamycin reaches patients quickly and effectively, thereby enhancing the company's market position in the rare disease sector.
See More
